MaxCyte Inc expected to post a loss of 11 cents a share - Earnings Preview
MaxCyte Inc
MXCT is expected to show a rise in quarterly revenue when it reports results on November 5 for the period ending September 30 2025The Rockville Maryland-based company is expected to report a 2.5% increase in revenue to $8.37 million from $8.16 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for MaxCyte Inc is for a loss of 11 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for MaxCyte Inc is $5.72, about 73.1% above its last closing price of $1.54
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.10 | -0.10 | -0.12 | Missed | -16.1 |
Mar. 31 2025 | -0.11 | -0.10 | -0.10 | Met | 4.8 |
Dec. 31 2024 | -0.11 | -0.12 | -0.10 | Beat | 18 |
Sep. 30 2024 | -0.12 | -0.12 | -0.11 | Beat | 10.8 |
Jun. 30 2024 | -0.13 | -0.13 | -0.09 | Beat | 28.9 |
Mar. 31 2024 | -0.13 | -0.13 | -0.09 | Beat | 30.8 |
Dec. 31 2023 | -0.07 | -0.07 | -0.05 | Beat | 30.6 |
Sep. 30 2023 | -0.10 | -0.10 | -0.11 | Missed | -7.8 |
This summary was machine generated November 3 at 21:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
